上(shang)海(hai)復星醫藥（集團）股份有限公司公布(bu)2022年上(shang)半(ban)年經(jing)(jing)營(ying)(ying)業(ye)(ye)績。 2022年上(shang)半(ban)年，復星醫藥營(ying)(ying)業(ye)(ye)收(shou)入(ru)(ru)和經(jing)(jing)常(chang)性(xing)收(shou)益(yi)繼(ji)續保持(chi)穩健增長(chang)，新(xin)產(chan)(chan)品(pin)和次新(xin)品(pin)收(shou)入(ru)(ru)占比及中國(guo)大陸以(yi)外(wai)地區(qu)和其他(ta)(ta)國(guo)家收(shou)入(ru)(ru)占比持(chi)續提升，收(shou)入(ru)(ru)結(jie)構持(chi)續優化。報(bao)告期(qi)內(nei)，復星醫藥實現(xian)(xian)營(ying)(ying)業(ye)(ye)收(shou)入(ru)(ru)213.40億元，同(tong)(tong)(tong)比增長(chang)25.88%，實現(xian)(xian)歸屬于上(shang)市公司股東的扣除非(fei)經(jing)(jing)常(chang)性(xing)損益(yi)的凈(jing)利潤18.62億元，同(tong)(tong)(tong)比增長(chang)18.57%；經(jing)(jing)營(ying)(ying)活動產(chan)(chan)生的現(xian)(xian)金流量(liang)凈(jing)額18.20億元，同(tong)(tong)(tong)比增長(chang)6.66%。全球化運(yun)營(ying)(ying)能力持(chi)續提升，報(bao)告期(qi)內(nei)，中國(guo)大陸以(yi)外(wai)地區(qu)和其他(ta)(ta)國(guo)家收(shou)入(ru)(ru)75.92億元，占營(ying)(ying)業(ye)(ye)收(shou)入(ru)(ru)比重達(da)35.58%，同(tong)(tong)(tong)比提升4.92個百(bai)分點。(醫藥健聞)